Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun 1;5(1):23.
doi: 10.1186/s42466-023-00249-5.

Design and implementation of ParkinsonAKTIV: an interventional study to evaluate the effectiveness of a novel online platform to guide quickcard-based treatment decisions

Affiliations

Design and implementation of ParkinsonAKTIV: an interventional study to evaluate the effectiveness of a novel online platform to guide quickcard-based treatment decisions

Katharina Achtert et al. Neurol Res Pract. .

Abstract

Introduction: Patients with Parkinson's Disease (PD) require an all-encompassing and individualized care including pharmacological as well as non-pharmacological treatment approaches, such as physical therapy, occupational therapy and speech and swallowing therapy. ParkinsonAKTIV is an innovative, multidisciplinary, and comprehensive approach to guide this non-pharmacological PD treatment in northwestern Germany. Its online communication platform called JamesAKTIV has been developed to enhance and standardize PD healthcare professionals' communication. The implementation of ParkinsonAKTIV and JamesAKTIV is accompanied through a detailed process evaluation and to gather evidence on the impact on patient-related outcomes, such as health-related quality of life and healthcare costs for people with PD through an effectiveness evaluation.

Methods: The study design contains two parts: (1) first, a quantitative effectiveness evaluation is conducted utilizing a prospective quasi-experimental approach with a control group which examines PD patient's health-related quality of life and physician-assessed PD patient's health status (Unified Parkinson Disease Rating Scale). Moreover, a health economic evaluation of the ParkinsonAKTIV intervention is conducted using patient-reported outcomes and cost data as well as routine data from a statutory health insurance. (2) Second, a mixed-methods process evaluation among healthcare professionals, which examines the feasibility and potential barriers and facilitators of ParkinsonAKTIV for routine care, is performed. Quantitative results from a social network analysis and a survey among healthcare professionals will be triangulated with data from qualitative stakeholder interviews and focus group discussions.

Perspective: Findings are expected to provide evidence of an increase in quality of life of patients with PD, less severe PD symptoms, and a better ability to participate in activities of daily living. ParkinsonAKTIV has the potential of increasing PD patients' quality of care through sufficient and more tailored prescription of non-pharmacological therapies. It is anticipated that ParkinsonAKTIV will improve communication among health professionals. Results from the ParkinsonAKTIV study will provide first practice-oriented evidence and a roadmap for implementation of an online tool for a comprehensive, multidisciplinary care PD network for patients and their caregivers in routine care in Germany. Trial registration ClinicalTrials.gov: registration number NCT05251298 (retrospectively registered: https://clinicaltrials.gov/ct2/show/record/NCT05251298 ).

Keywords: Economic evaluation; Efficacy; Innovative care approach; Neurodegenerative disease; Nonpharmacological treatment; Parkinson’s disease; Process evaluation; Social network analysis; Study protocol.

PubMed Disclaimer

Conflict of interest statement

Tessa Huchtemann has received honoria from Esteve and Licher, and funding from Bundeskongress Physiotherapie. Tobias Warnecke has received honoraria from BIAL, Abbvie, Desitin, Pfitzer, Britannia, Esteve and Licher, consultancies from Stada and Phagenesis, and funding from Abbvie.

Figures

Fig. 1
Fig. 1
Illustration of JamesAKTIV

References

    1. Berger K, Broll S, Winkelmann J, Heberlein I, Müller T, Ries V. Untersuchung zur Reliabilität der deutschen Version des PDQ-39: Ein krankheitsspezifischer Fragebogen zur Erfassung der Lebensqualität von Parkinson-Patienten. Aktuelle Neurologie. 1999;26(04):180–184. doi: 10.1055/s-2007-1017628. - DOI
    1. Blanchet K, James P. How to do (or not to do)… a social network analysis in health systems research. Health Policy and Planning. 2012;27(5):438–446. doi: 10.1093/heapol/czr055. - DOI - PubMed
    1. Curran GM, Bauer M, Mittman B, Pyne JM, Stetler C. Effectiveness-implementation hybrid designs: Combining elements of clinical effectiveness and implementation research to enhance public health impact. Medical Care. 2012;50(3):217. doi: 10.1097/MLR.0b013e3182408812. - DOI - PMC - PubMed
    1. Deuschl, G., Oertel, W., & Reichmann, H. (2016). Deutsche Gesellschaft für Neurologie S3-Leitlinie Parkinson-Syndrom, idiopathisch [23.07.2020]. Retrieved from https://register.awmf.org/de/leitlinien/detail/030-010
    1. Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, Dubois B. Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. Movement Disorders: Official Journal of the Movement Disorder Society. 2008;23(15):2129–2170. doi: 10.1002/mds.22340. - DOI - PubMed

Associated data

LinkOut - more resources